Chinese FDA listing for synthetic peptides SYN®-AKE and SYN®-HYCAN from DSM
This is the latest highlight in the ten years success story of DSM’s patented SYN® synthetic peptides portfolio. Encouraged by customers that have persistently raised their interest and demand for additional SYN-Peptides, this new listing is in a very important region and joins SYN-COLL, which was already listed by CFDA in September 2012. Through the new listings and by providing formulations tailored to different customer needs, the usage of more SYN-Peptides will be significantly expanded. This substantiates DSM’s position and reputation as one of the leading players in synthetic bioactive peptides and motivates the company to continue with its commitment to further invest into this key technology.
Mathias Gempeler, Senior Global Marketing Manager Skin Care at DSM, comments: “We believe that the new listings in China will open exciting opportunities for customers focusing on this key high growth economy. The latest decision by the Chinese Food & Drug Administration supports DSM’s passion and creativity to craft innovations that truly meet people’s beauty aspirations around the globe.”